论文部分内容阅读
[目的]观察阿德福韦联合苦参素治疗HBeAg阴性慢性乙型肝炎的疗效。[方法]分为治疗组(阿德福韦联合苦参素)和对照组(阿德福韦),每组60例患者,疗程1年半。[结果]两组治疗3,6,12,月后丙氨酸转氨酶(ALT)复常率分别为78.3%、85.0%、91.6%、和66.6%、78.3%、73.3%,两组比较差异无统计学意义;HBV-DNA阴转率分别为56.7%、73.3%、85.0%、和55.0%、81.6%、71.6%、,两组比较差异无统计学意义;但疗程结束(18个月)后,两组ALT复常率分别为93.3%和55.0%;HBV-DNA阴转率分别为76.6%和45.0%;两组比较差异有统计学意义(P﹤0.05)。完全应答率分别为78.3%和46.6%;持续应答率分别为66.6%和30.0%,两组比较差异有统计学意义(P﹤0.05)。[结论]阿德福韦联合苦参素治疗HBeAg阴性慢性乙型肝炎的疗效较好,且疗程结束后持续应答率好,值得在临床上推广应用。
[Objective] To observe the efficacy of adefovir combined with oxymatrine in the treatment of HBeAg-negative chronic hepatitis B. [Methods] Divided into treatment group (adefovir combined with matrine) and control group (adefovir), 60 patients in each group, the course of treatment for 1.5 years. [Results] The normalization rates of alanine aminotransferase (ALT) were 78.3%, 85.0%, 91.6%, and 66.6%, 78.3% and 73.3% in both groups at 3, 6, 12 months after treatment, with no significant difference between the two groups The negative rates of HBV DNA were 56.7%, 73.3%, 85.0%, 55.0%, 81.6%, 71.6%, respectively. There was no significant difference between the two groups after treatment (18 months) . The rates of ALT normalization in the two groups were 93.3% and 55.0%, respectively. The negative rates of HBV DNA were 76.6% and 45.0% respectively. There was significant difference between the two groups (P <0.05). The complete response rates were 78.3% and 46.6% respectively. The sustained response rates were 66.6% and 30.0% respectively, with significant difference between the two groups (P <0.05). [Conclusion] adefovir combined with oxymatrine in the treatment of HBeAg-negative chronic hepatitis B has a good curative effect, and the continuous response rate after the end of treatment is good, so it is worth popularizing and applying in clinic.